- Home
- TLPH vs LYRA Comparison
TLPH vs LYRA Comparison
Compare TLPH & LYRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TLPH
- LYRA
- Stock Information
- Founded
- TLPH 2005
- LYRA 2005
- Country
- TLPH United States
- LYRA United States
- Employees
- TLPH N/A
- LYRA N/A
- Industry
- TLPH Biotechnology: Pharmaceutical Preparations
- LYRA Medical/Dental Instruments
- Sector
- TLPH Health Care
- LYRA Health Care
- Exchange
- TLPH Nasdaq
- LYRA Nasdaq
- Market Cap
- TLPH 13.4M
- LYRA 11.0M
- IPO Year
- TLPH 2011
- LYRA 2020
- Fundamental
- Price
- TLPH $0.73
- LYRA $0.19
- Analyst Decision
- TLPH Strong Buy
- LYRA Buy
- Analyst Count
- TLPH 2
- LYRA 5
- Target Price
- TLPH $4.50
- LYRA $4.50
- AVG Volume (30 Days)
- TLPH 67.4K
- LYRA 2.6M
- Earning Date
- TLPH 11-13-2024
- LYRA 11-12-2024
- Dividend Yield
- TLPH N/A
- LYRA N/A
- EPS Growth
- TLPH N/A
- LYRA N/A
- EPS
- TLPH N/A
- LYRA N/A
- Revenue
- TLPH $281,000.00
- LYRA $1,471,000.00
- Revenue This Year
- TLPH N/A
- LYRA $13.99
- Revenue Next Year
- TLPH N/A
- LYRA N/A
- P/E Ratio
- TLPH N/A
- LYRA N/A
- Revenue Growth
- TLPH N/A
- LYRA 3.37
- 52 Week Low
- TLPH $0.61
- LYRA $0.16
- 52 Week High
- TLPH $1.61
- LYRA $6.79
- Technical
- Relative Strength Index (RSI)
- TLPH 35.76
- LYRA 40.68
- Support Level
- TLPH $0.66
- LYRA $0.16
- Resistance Level
- TLPH $0.73
- LYRA $0.20
- Average True Range (ATR)
- TLPH 0.08
- LYRA 0.02
- MACD
- TLPH -0.02
- LYRA -0.00
- Stochastic Oscillator
- TLPH 15.55
- LYRA 26.24
About TLPH Talphera Inc.
Talphera Inc. is a pharmaceutical company focused on the development and commercialization of therapies for use in medically supervised settings. Its portfolio consists of nafamostat product candidates and pre-filled syringe product candidates.
About LYRA Lyra Therapeutics Inc.
Lyra Therapeutics Inc is a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases. The Company's operations and manages its business as a single operating segment which is the business of developing targeted medicines to address ears, nose, and throat, or ENT diseases. Its initial product candidates, LYR-210 and LYR-220, are bioresorbable polymeric matrices designed to be administered in a brief, non-invasive, in-office procedure and intended to deliver up to six months of continuous drug therapy to the sinonasal passages for the treatment of chronic rhinosinusitis, or CRS.